China Pharma (CPHI) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 09, 2022
Document Information Line Items
Entity Registrant Name	CHINA PHARMA HOLDINGS, INC.
Trading Symbol	CPHI
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		48,299,971
Amendment Flag	false
Entity Central Index Key	0001106644
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-34471
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	75-1564807
Entity Address, Address Line One	Second Floor, No. 17, Jinpan Road
Entity Address, Address Line Two	Haikou
Entity Address, City or Town	Hainan Province
Entity Address, Country	CN
Entity Address, Postal Zip Code	570216
City Area Code	+86
Local Phone Number	898-6681-1730
Title of 12(b) Security	Common Stock
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 3,714,810	$ 4,859,059
Banker’s acceptances	14,146	91,362
Trade accounts receivable, less allowance for doubtful accounts of $18,384,642 and $18,312,707, respectively	418,650	714,475
Other receivables, less allowance for doubtful accounts of $30,716 and $32,210, respectively	39,019	29,564
Advances to suppliers	473	471
Inventory	3,906,394	3,339,686
Prepaid expenses	71,788	58,792
Total Current Assets	8,165,280	9,093,409
Property, plant and equipment, net	12,632,038	13,280,559
Operating lease right of use asset	107,094	127,958
Intangible assets, net	138,798	147,841
TOTAL ASSETS	21,043,210	22,649,767
Current Liabilities:
Trade accounts payable	927,350	926,749
Accrued expenses	138,221	298,452
Other payables	1,757,061	1,884,161
Advances from customers	136,099	210,028
Borrowings from related parties	2,557,039	2,779,690
Operating lease liability	86,672	85,282
Construction loan facility
Current portion of lines of credit	4,300,432	4,328,936
Total Current Liabilities	9,902,874	10,513,298
Non-current Liabilities:
Convertible, redeemable note payable	4,950,000	5,250,000
Lines of credit, net of current portion
Operating lease liability, net of current portion	22,318	44,181
Deferred tax liability	827,978	824,407
Total Liabilities	15,703,170	16,631,886
Commitments and Contingencies (Note 9)
Stockholders’ Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 95,000,000 shares authorized; 48,299,971 shares and 47,339,557 shares issued and outstanding, respectively	48,300	47,340
Additional paid-in capital	25,944,407	25,645,367
Retained deficit	(33,268,145)	(32,238,655)
Accumulated other comprehensive income	12,615,478	12,563,829
Total Stockholders’ Equity	5,340,040	6,017,881
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 21,043,210	$ 22,649,767

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Trade accounts receivable, less allowance for doubtful accounts (in Dollars)	$ 18,384,642	$ 18,312,707
Other receivables, less allowance for doubtful accounts (in Dollars)	$ 30,716	$ 32,210
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	48,299,971	47,339,557
Common stock, shares outstanding	48,299,971	47,339,557

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue	$ 1,604,005	$ 2,358,371
Cost of revenue	1,773,466	2,085,641
Gross profit (loss)	(169,461)	272,730
Operating expenses:
Selling expenses	179,561	378,335
General and administrative expenses	514,168	408,998
Research and development expenses	54,049	190,086
Bad debt benefit	(5,521)	(8,221)
Total operating expenses	742,257	969,198
Loss from operations	(911,718)	(696,468)
Other income (expense):
Interest income	6,655	406
Interest expense	(124,427)	(71,265)
Net other expense	(117,772)	(70,859)
Loss before income taxes	(1,029,490)	(767,327)
Income tax expense
Net loss	(1,029,490)	(767,327)
Other comprehensive income (loss) - foreign currency translation adjustment	51,649	(71,325)
Comprehensive loss	$ (977,841)	$ (838,652)
Loss per share:
Basic and diluted (in Dollars per share)	$ (0.02)	$ (0.02)
Weighted average shares outstanding (in Shares)	47,368,111	45,579,557

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Accumulated Other Comprehensive Income	Total
Balance at Dec. 31, 2020	$ 45,580	$ 24,452,684	$ (28,839,179)	$ 12,345,446	$ 8,004,531
Balance (in Shares) at Dec. 31, 2020	45,579,557
Net loss for the period			(767,327)		(767,327)
Foreign currency translation adjustment				(741,325)	(741,325)
Balance at Mar. 31, 2021	$ 45,580	24,452,684	(29,606,506)	11,604,121	6,495,879
Balance (in Shares) at Mar. 31, 2021	45,579,557
Balance at Dec. 31, 2021	$ 47,340	25,645,367	(32,238,655)	12,563,829	6,017,881
Balance (in Shares) at Dec. 31, 2021	47,339,557
Conversions of Note Payable to common stock	$ 960	299,040			300,000
Conversions of Note Payable to common stock (in Shares)	960,414
Net loss for the period			(1,029,490)		(1,029,490)
Foreign currency translation adjustment				51,649	51,649
Balance at Mar. 31, 2022	$ 48,300	$ 25,944,407	$ (33,268,145)	$ 12,615,478	$ 5,340,040
Balance (in Shares) at Mar. 31, 2022	48,299,971

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash Flows from Operating Activities:
Net loss	$ (1,029,490)	$ (767,327)
Depreciation and amortization	713,557	700,187
Bad debt (benefit) expense	(5,521)	(8,221)
Inventory write off	10,164	54,145
Changes in assets and liabilities:
Trade accounts and other receivables	258,130	(275,821)
Advances to suppliers		(1,474)
Inventory	(447,745)	211,393
Trade accounts payable	(3,413)	(115,768)
Other payables and accrued expenses	(290,893)	60,704
Change in bankers’ acceptance notes payable
Advances from customers	(74,814)	(144,602)
Prepaid expenses	(9,414)	9,868
Net Cash Used in Operating Activities	(879,439)	(276,916)
Cash Flows from Investing Activities:
Purchases of property and equipment	(1,391)
Net Cash Used in Investing Activities	(1,391)
Cash Flows from Financing Activities:
Payments of construction term loan		(154,215)
Payments of line of credit	(47,241)	(46,265)
Borrowings and interest from related party	7,669	306,688
Repayments to related party	(236,206)	(251,371)
Net Cash (Used In) Provided By Financing Activities	(275,778)	(145,163)
Effect of Exchange Rate Changes on Cash	12,358	(1,044)
Net Increase in Cash, Cash Equivalents and Restricted Cash	(1,144,250)	(423,123)
Cash and Cash Equivalents at Beginning of Period	4,859,060	957,653
Cash, Cash Equivalents and Restricted Cash at End of Period	3,714,810	534,530
Supplemental Cash Flow Information:
Cash paid for income taxes
Cash paid for interest	218,232	60,368
Supplemental Noncash Investing and Financing Activities:
Accounts receivable collected with banker’s acceptances	36,885	194,641
Inventory purchased with banker’s acceptances	114,471	$ 248,713
Conversions of Note Payable to common stock	$ 300,000

Organization and Significant Ac

Organization and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Organization and Nature of Operations – Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (“WFOE”) status on June 21, 2005. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy. Liquidity and Going Concern As of March 31, 2022, the Company had cash and cash equivalents of $3.7 million and an accumulated deficit of $33.3 million. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $1,202,472 at March 31, 2022 to provide working capital and enable the Company to make the required payments related to its prior construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Consolidation and Basis of Presentation Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessary be indicative of annual results. Such financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2022 (“the 2021 Annual Report”). Accounting Estimates The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Loss Per Share The potentially dilutive common shares related to the Convertible, redeemable note payable of 12,493,690 and 11,975,447 as of March 31, 2022 and December 31, 2021 as discussed in Note 8, respectively, and the option to purchase 65,000 shares of common stock as of March 31, 2022 and December 31, 2021 are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company. Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326) In 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer’s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity’s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. The pronouncement will be effective for public business entities that are SEC smaller reporting company filers in fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted the standard during fiscal 2021. From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
INVENTORY	NOTE 2 – INVENTORY Inventory consisted of the following: March 31, December 31, 2022 2021 Raw materials 2,280,072 2,131,584 Work in process 476,631 622,380 Finished goods 1,149,692 585,722 Total Inventory $ 3,906,394 $ 3,339,686

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 3 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consisted of the following: March 31, December 31, 2022 2021 Permit of land use $ 443,697 $ 441,783 Building 10,303,326 10,258,885 Plant, machinery and equipment 30,249,997 30,122,235 Motor vehicle 338,836 337,375 Office equipment 280,893 278,892 Total 41,616,749 41,439,170 Less: accumulated depreciation (28,984,711 ) (28,158,611 ) Property, plant and equipment, net $ 12,632,038 $ 13,280,559 Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: Asset Life - years Permit of land use 40 - 70 Building 20 - 49 Plant, machinery and equipment 5 - 10 Motor vehicle 5 - 10 Office equipment 3-5 Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was $703,877 and $690,707 for the three months ended March 31, 2022 and 2021, respectively.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 4 - INTANGIBLE ASSETS Intangible assets represent the cost of medical formulas approved for production by the NMPA. The Company did not obtain NMPA production approval for any new medical formulas during the three months ended March 31, 2022 and 2021 and no costs were reclassified from advances to intangible assets during the three months ended March 31, 2022 and 2021, respectively. Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $9,680 and $9,480 for the three months ended March 31, 2022 and 2021, respectively, which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period. The Company evaluates each approved medical formula for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial statement. The Company’s evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data for the related drug and the Company’s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the three months ended March 31, 2022 and 2021. Intangible assets consisted solely of NMPA approved medical formulas as follows: March 31, December 31, 2022 2021 Gross carrying amount $ 5,317,829 $ 5,294,892 Accumulated amortization (5,179,031 ) (5,147,051 ) Net carrying amount $ 138,798 $ 147,841

Other Payables

Other Payables	3 Months Ended
	Mar. 31, 2022
Other Payables [Abstract]
OTHER PAYABLES	NOTE 5 – OTHER PAYABLES Other Payables consisted of the following: March 31, December 31, 2022 2021 Compensation payable to officer $ 719,506 $ 715,506 Compensation and interest to related parties 338,419 327,033 Business taxes and other 699,136 841,622 Total Other Payables $ 1,757,061 $ 1,884,161

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6 – RELATED PARTY TRANSACTIONS A member of the Company’s board of directors (“Board”) had previously advanced to the Company an aggregate amount of $1,354,567 as of March 31, 2022 and December 31, 2021 which is recorded as “Borrowings from related parties” on the accompanying condensed consolidated balance sheets. The advances bear interest at a rate of 1.0% per year. Total interest expense for each of the three months ended March 31, 2022 and 2021 was $3,386 and $3,386, respectively. Compensation and interest payable to the board member is included in “Other payables” in the accompanying condensed consolidated balance sheet totaling $338,414 and $327,033 as of March 31, 2022 and December 31, 2021, respectively. The Company repaid $236,206 of the advances during the three months ended March 31, 2022 from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. Total amounts owed were $1,202,872 and $1,183,414 and are recorded as “Borrowings from related parties” on the accompanying condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021, respectively. On July 8, 2019 the Company entered into a loan agreement in exchange for cash of RMB 4,770,000 ($738,379) with its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the loan agreement. The due date of the loan agreement was extended to July 10, 2021 and further extended to July 9, 2022 on identical terms. Total interest expense related to the loan for the three months ended March 31, 2022 and 2021 was $7,669 and $7,510, respectively. Compensation payable to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer is included in “Other payables” in the accompanying condensed consolidated balance sheet totaling $719,506 and $715,506 as of March 31, 2022 and December 31, 2021, respectively.

Lines of Credit

Lines of Credit	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
LINES OF CREDIT	NOTE 7 – LINES OF CREDIT In April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000 (approximately $0.7 million) was advanced in April 2020, and RMB 3,000,000 (approximately $0.4 million) was advanced in July 2020. The loan bears interest at a rate of 4.25% per annum. Advances on the line of credit are due two years from the date of the advance. A third party company has guaranteed the loan as being a second priority creditor in the collateral in certain land use rights and buildings next to Bank of China. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. The Company has remaining RMB 2,000,000 (approximately $0.3 million) available under the line, subject to a risk review and approval by the third party guarantee company. Total interest expense under this facility for the three months ended March 31, 2022 and 2021 was $9,445 and $11,967, respectively. The Company repaid RMB 300,000 (approximately $0.05 million) during the three months ended March 31, 2022 as per the repayment schedule. On June 30, 2020 the Company obtained a line of credit with Bank of Communications for an aggregate amount of RMB 8,500,000 (approximately $1.2 million), all of which has been advanced. The loan bears interest at the rate of 4.05% per annum. The line of credit is due in one year on the anniversary date of the line of credit. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. On June 21, 2021 the Company paid the balance in full. On June 25, 2021 the Company entered into a new loan bearing an interest rate of 4.17%. The line of credit is due in one year on the anniversary date of the line of credit. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest expense for the three months ended March 31, 2022 and 2021 was $13,954 and $13,272, respectively. The Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October 2020 under this line. The loan bears interest at the rate of 4.50% per annum. In September 2021, the Company repaid the line of credit in full, Also in September 2021, the Company entered into a new line a credit in the amount of RMB 3,200,000 (approximately $0.8 million) on the same terms. The line of credit is due on September 2, 2022. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest for the three months ended March 31, 2022 and 2021 was $5,669 and $5,552, respectively. On September 18, 2021 the Company obtained a line of credit for RMB 10,000,000 (approximately $1.54 million) with Bank of China. The loan bears interest at the rate of 3.85% per annum. The line of credit is due September 18, 2022. The loan is collateralized by the Company’s new production facility and the included production line equipment and machinery. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. Total interest for the three months ended March 31, 2022 and 2021 was $15,157 and $0, respectively. Principal payments required for the remaining terms of the loan facility and lines of credit as of March 31, 2022 are as follows: Year Lines of 2022 $ 4,300,432 $ 4,300,432 Fair Value of Lines of Credit

Convertible Note Payable

Convertible Note Payable	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
CONVERTIBLE NOTE PAYABLE	NOTE 8 – CONVERTIBLE NOTE PAYABLE On November 17, 2021, the Company entered into a Securities Purchase Agreement (the “Agreement”) pursuant to which the Company issued an unsecured convertible promissory note (the “Note”) to an institutional accredited investor Streeterville Capital, LLC (the “Investor”). The Note matures fifteen months after the purchase price of the Note is delivered from the Investor to the Company (the “Purchase Price Date”). The Note has the original principal amount of $5,250,000 and Investor gave consideration of $5,000,000, reflecting original issue discount of $250,000. The transaction contemplated under the Agreement was closed on November 19, 2021 and the Company has been using the proceeds for general working capital purposes. The Note balance of $4,950,000 as of March 31, 2022 is convertible into 3,300,000 shares of the Company’s common stock at a price of $1.50 per share through April 19, 2022. Thereafter, the Note is convertible into 1,650,000 shares at a price of $3.00 per share. Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default. Pursuant to the terms of the Agreement and the Note, the Company must obtain Investor’s consent for certain fundamental transactions such as consolidation, merger with or into another entity (excerpt for a reincorporation merger), disposition of substantial assets, change of control, reorganization or recapitalization. Any occurrence of a fundamental transaction without Investor’s prior written consent will be deemed an Event of Default. Investor may redeem all or any part the outstanding balance of the Note, subject to $500,000 per calendar month, at any time after one hundred twenty-one (121) days from the Purchase Price Date upon three trading days’ notice, in cash or converting into shares of the Company’s common stock, at a price equal to 85% multiplied by the lowest daily volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations specified in the Note. The Note provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note. The Company may prepay the outstanding balance of the Note with the Investor’s consent. At inception, the Note was redeemable into 8,811,430 shares based on the lowest volume weighted average price of $0.595817 on the inception date of November 19, 2021. As of March 31, 2022 and December 31, 2021, the Note was redeemable into 12,493,690 and 11,975,447 shares of common stock, respectively based on the lowest volume weighted average price of $0.3962 and $0.4384 on those dates, respectively. Total interest expense for the three months ended March 31, 2022 and 2021 was $67,686 and $0, respectively. On March 21, 2022 the Investor delivered its notice of redemption for $100,000 of the Note and related interest at the price of $0.3113, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 321,233 shares of common stock to the Investor on March 23, 2022. On March 30, 2022 the Investor delivered its notice of redemption for $200,000 of the Note and related interest at the price of $0.3129, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 639,181 shares of common stock to the Investor on March 31, 2022.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
LEASES	NOTE 9 - LEASES The Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right to use assets when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company’s incremental borrowing rate at the initial measurement date. For the three months ended March 31, 2022 and 2021, operating lease cost was $21,419 and $23,968, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $22,495 and $25,475, respectively. As of March 31, 2022 and December 31, 2021, the Company reported operating lease right of use assets of $107,094 and $127,958, respectively and operating use liabilities of $108,990 and $129,462, respectively. As of March 31, 2022, its operating leases had a weighted average remaining lease term of 1.25 years and a weighted average discount rate of 4.75%. Minimum lease payments for the Company’s operating lease liabilities were as follows for the twelve month periods ended March 31: 2023 $ 89,978 2024 22,494 Total undiscounted cash flows 112,472 Less: Imputed interest (3,482 ) 108,990 Less: Operating lease liabilities, current portion (86,672 ) Operating lease liabilities, net of current portion $ 22,318 The Company has leases with terms less than one year for certain provincial sales offices that are not material.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 10 - INCOME TAXES Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the “more-likely-than-not” threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2021, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2017 through December 31, 2021 and the Chinese income tax return for the year ended December 31, 2021 are open for possible examination. Under the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of 25%. There was no provision for income taxes for the three months ended March 31, 2022 and 2021, respectively due to continued net losses of the Company. As of March 31, 2022, the Company had net operating loss carryforwards for PRC tax purposes of approximately $23.8 million which are available to offset any future taxable income through 2027. Approximately $4.4 million of these carryforwards will expire in December 2022. The Company also has net operating losses for United States federal income tax purposes of approximately $8.0 million of which $5.1 million is available to offset future taxable income, if any, through 2039, and $2.9 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year. U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the “U.S. Tax Reform”), was signed into law on December 22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of March 31, 2022 and December 31, 2021. Therefore, the Company provided for a valuation allowance against its deferred tax assets of $24,318,296 and $23,982,509 as of March 31, 2022 and December 31, 2021, respectively. The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 11 – FAIR VALUE MEASUREMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities; Level 2 – Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data; and Level 3 – Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. The Company uses fair value to measure the value of the banker’s acceptance notes it holds at March 31, 2022 and December 31, 2021. The banker’s acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value: Fair Value Measurements at March 31, Reporting Date Using Description 2022 Level 1 Level 2 Level 3 Banker’s acceptance notes $ 14,146 $ - $ 14,146 $ - Total $ 14,146 $ - $ 14,146 $ - Fair Value Measurements at December 31, Reporting Date Using Description 2021 Level 1 Level 2 Level 3 Banker’s acceptance notes $ 91,362 $ - $ 91,362 $ - Total $ 91,362 $ - $ 91,362 $ -

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 12 - STOCKHOLDERS’ EQUITY The Company is authorized to issue 95,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company’s Board. According to relevant PRC laws, companies registered in the PRC, including the Company’s PRC subsidiary, Helpson, are required to allocate at least 10% of their after tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach 50% of the company’s registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is $8,145,000 as of March 31, 2022 and December 31, 2021. 2022 Share Issuances On March 21, 2022 the Investor as discussed in Note 8 delivered its notice of redemption for $100,000 of the Note and related interest at the lowest volume weighted average price of $0.3113 during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 321,233 shares of common stock to the Investor on March 23, 2022. On March 30, 2022 the Investor as discussed in Note 8 delivered its notice of redemption for $200,000 of the Note and related interest at the lowest volume weighted average price of $0.3129 during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 639,181 shares of common stock to the Investor on March 31, 2022. 2010 Incentive Plan On November 12, 2010, the Company’s Board adopted the Company’s 2010 Incentive Plan (the “Plan”), which was then approved by stockholders on December 22, 2010. On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the “Amendment”), pursuant to which the term of the 2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December 19, 2019. On October 25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to the Plan to increase the number of shares of the Common Stock, that are reserved thereunder by 5,000,000 shares from 4,000,000 shares to 9,000,000 shares. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 9,000,000 shares of common stock. Through March 31, 2022, there were 3,935,000 shares of stock granted and outstanding under the Plan. A total of 65,000 options were outstanding as of March 31, 2022 under the Plan. As such, there are 5,000,000 additional shares available for issuance under the Plan. As of March 31, 2022, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.

Risks & Uncertainties

Risks & Uncertainties	3 Months Ended
	Mar. 31, 2022
Risks and Uncertainties [Abstract]
RISKS & UNCERTAINTIES	NOTE 13 – RISKS & UNCERTAINTIES Current vulnerability due to certain concentrations For the three months ended March 31, 2022, no customer accounted for more than 10% of sales and three customers accounted for 53.0%, 11.4% and 10.4% of accounts receivable. Two suppliers accounted for 29.2% and 28.4% of raw material purchases, and three different products accounted for 32.5%, 29.4% and 12.7% of revenue. Nature of Operations Impact from the New Coronavirus Global Pandemic (“COVID-19”) Economic environment - In addition, all of the Company’s revenue is denominated in the PRC’s currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Organization and Nature of Operations	Organization and Nature of Operations – Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (“WFOE”) status on June 21, 2005. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.
Liquidity and Going Concern	Liquidity and Going Concern As of March 31, 2022, the Company had cash and cash equivalents of $3.7 million and an accumulated deficit of $33.3 million. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $1,202,472 at March 31, 2022 to provide working capital and enable the Company to make the required payments related to its prior construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
Consolidation and Basis of Presentation	Consolidation and Basis of Presentation Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessary be indicative of annual results. Such financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2022 (“the 2021 Annual Report”).
Accounting Estimates	Accounting Estimates The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.
Loss Per Share	Loss Per Share The potentially dilutive common shares related to the Convertible, redeemable note payable of 12,493,690 and 11,975,447 as of March 31, 2022 and December 31, 2021 as discussed in Note 8, respectively, and the option to purchase 65,000 shares of common stock as of March 31, 2022 and December 31, 2021 are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326) In 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer’s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity’s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. The pronouncement will be effective for public business entities that are SEC smaller reporting company filers in fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted the standard during fiscal 2021. From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of inventory	March 31, December 31, 2022 2021 Raw materials 2,280,072 2,131,584 Work in process 476,631 622,380 Finished goods 1,149,692 585,722 Total Inventory $ 3,906,394 $ 3,339,686

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	March 31, December 31, 2022 2021 Permit of land use $ 443,697 $ 441,783 Building 10,303,326 10,258,885 Plant, machinery and equipment 30,249,997 30,122,235 Motor vehicle 338,836 337,375 Office equipment 280,893 278,892 Total 41,616,749 41,439,170 Less: accumulated depreciation (28,984,711 ) (28,158,611 ) Property, plant and equipment, net $ 12,632,038 $ 13,280,559
Schedule of estimated useful lives of the assets	Asset Life - years Permit of land use 40 - 70 Building 20 - 49 Plant, machinery and equipment 5 - 10 Motor vehicle 5 - 10 Office equipment 3-5

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	March 31, December 31, 2022 2021 Gross carrying amount $ 5,317,829 $ 5,294,892 Accumulated amortization (5,179,031 ) (5,147,051 ) Net carrying amount $ 138,798 $ 147,841

Other Payables (Tables)

Other Payables (Tables)	3 Months Ended
	Mar. 31, 2022
Other Payables [Abstract]
Schedule of other payables	March 31, December 31, 2022 2021 Compensation payable to officer $ 719,506 $ 715,506 Compensation and interest to related parties 338,419 327,033 Business taxes and other 699,136 841,622 Total Other Payables $ 1,757,061 $ 1,884,161

Lines of Credit (Tables)

Lines of Credit (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of principal payments	Year Lines of 2022 $ 4,300,432 $ 4,300,432

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure Text Block [Abstract]
Schedule of operating lease liabilities	2023 $ 89,978 2024 22,494 Total undiscounted cash flows 112,472 Less: Imputed interest (3,482 ) 108,990 Less: Operating lease liabilities, current portion (86,672 ) Operating lease liabilities, net of current portion $ 22,318

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities recorded at fair value	Fair Value Measurements at March 31, Reporting Date Using Description 2022 Level 1 Level 2 Level 3 Banker’s acceptance notes $ 14,146 $ - $ 14,146 $ - Total $ 14,146 $ - $ 14,146 $ - Fair Value Measurements at December 31, Reporting Date Using Description 2021 Level 1 Level 2 Level 3 Banker’s acceptance notes $ 91,362 $ - $ 91,362 $ - Total $ 91,362 $ - $ 91,362 $ -

Organization and Significant _2

Organization and Significant Accounting Policies (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	May 25, 2005
Organization and Significant Accounting Policies (Details) [Line Items]
Cash and cash equivalents (in Dollars)	$ 3,700,000
Accumulated deficit (in Dollars)	$ 33,300,000
Shares issuable upon conversion of the convertible note payable	12,493,690	11,975,447
Purchase of common stock	65,000	65,000
Onny Investment Limited [Member]
Organization and Significant Accounting Policies (Details) [Line Items]
Equity method investment, ownership percentage	100.00%
Hainan Helpson Medical & Biotechnology Co., Ltd [Member]
Organization and Significant Accounting Policies (Details) [Line Items]
Equity method investment, ownership percentage	100.00%		100.00%
Management [Member]
Organization and Significant Accounting Policies (Details) [Line Items]
Working capital (in Dollars)	$ 1,202,472

Inventory (Details) - Schedule

Inventory (Details) - Schedule of inventory - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Schedule of inventory [Abstract]
Raw materials	$ 2,280,072	$ 2,131,584
Work in process	476,631	622,380
Finished goods	1,149,692	585,722
Total Inventory	$ 3,906,394	$ 3,339,686

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expanse	$ 703,877	$ 690,707

Property, Plant and Equipment_3

Property, Plant and Equipment (Details) - Schedule of property, plant and equipment - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Schedule of property, plant and equipment [Abstract]
Permit of land use	$ 443,697	$ 441,783
Building	10,303,326	10,258,885
Plant, machinery and equipment	30,249,997	30,122,235
Motor vehicle	338,836	337,375
Office equipment	280,893	278,892
Total	41,616,749	41,439,170
Less: accumulated depreciation	(28,984,711)	(28,158,611)
Property, plant and equipment, net	$ 12,632,038	$ 13,280,559

Property, Plant and Equipment_4

Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets	3 Months Ended
	Mar. 31, 2022
Permit of land use [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	40 years
Permit of land use [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	70 years
Building [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	20 years
Building [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	49 years
Plant, machinery and equipment [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	5 years
Plant, machinery and equipment [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	10 years
Motor vehicle [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	5 years
Motor vehicle [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	10 years
Office equipment [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	3 years
Office equipment [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	5 years

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets useful life, description	Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.
Amortization expense relating to intangible assets	$ 9,680	$ 9,480

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of intangible assets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Schedule of intangible assets [Abstract]
Gross carrying amount	$ 5,317,829	$ 5,294,892
Accumulated amortization	(5,179,031)	(5,147,051)
Net carrying amount	$ 138,798	$ 147,841

Other Payables (Details) - Sche

Other Payables (Details) - Schedule of other payables - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Schedule of other payables [Abstract]
Compensation payable to officer	$ 719,506	$ 715,506
Compensation and interest to related parties	338,419	327,033
Business taxes and other	699,136	841,622
Total Other Payables	$ 1,757,061	$ 1,884,161

Related Party Transactions (Det

Related Party Transactions (Details)	3 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Jul. 08, 2019USD ($)	Jul. 08, 2019CNY (¥)
Related Party Transactions (Details) [Line Items]
Advance received	$ 1,354,567		$ 1,354,567
Interest rate	1.00%
Interest expense	$ 3,386	$ 3,386
Other payables	338,414		327,033
Borrowings from related parties	1,202,872		1,183,414
Other payables	719,506		$ 715,506
Chief Executive Officer [Member]
Related Party Transactions (Details) [Line Items]
Advance received	236,206
Management [Member]
Related Party Transactions (Details) [Line Items]
Interest rate				4.35%	4.35%
Interest expense	$ 7,669	$ 7,510
Loan agreement to borrow cash				$ (738,379)	¥ 4,770,000

Lines of Credit (Details)

Lines of Credit (Details)	Sep. 18, 2021	Jun. 30, 2020USD ($)	Apr. 30, 2020	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Jun. 25, 2021	Jun. 30, 2020CNY (¥)
Lines of Credit (Details) [Line Items]
Lines of credit description		the Company obtained a line of credit with Bank of Communications for an aggregate amount of RMB 8,500,000 (approximately $1.2 million), all of which has been advanced. The loan bears interest at the rate of 4.05% per annum. The line of credit is due in one year on the anniversary date of the line of credit. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. On June 21, 2021 the Company paid the balance in full. On June 25, 2021 the Company entered into a new loan bearing an interest rate of 4.17%. The line of credit is due in one year on the anniversary date of the line of credit. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan.	the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000 (approximately $0.7 million) was advanced in April 2020, and RMB 3,000,000 (approximately $0.4 million) was advanced in July 2020. The loan bears interest at a rate of 4.25% per annum. Advances on the line of credit are due two years from the date of the advance. A third party company has guaranteed the loan as being a second priority creditor in the collateral in certain land use rights and buildings next to Bank of China. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. The Company has remaining RMB 2,000,000 (approximately $0.3 million) available under the line, subject to a risk review and approval by the third party guarantee company. Total interest expense under this facility for the three months ended March 31, 2022 and 2021 was $9,445 and $11,967, respectively. The Company repaid RMB 300,000 (approximately $0.05 million) during the three months ended March 31, 2022 as per the repayment schedule.
Line of credit amount		$ 1,200,000					¥ 8,500,000
Interest rates description		4.05%
Interest rate				1.00%
Total interest expense				$ 124,427	$ 71,265
Bank of Communications [Member]
Lines of Credit (Details) [Line Items]
Interest rate						4.17%
Total interest expense				13,954	13,272
China CITIC Bank [Member]
Lines of Credit (Details) [Line Items]
Total interest expense				$ 5,669	5,552
Line of credit, description				The Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October 2020 under this line. The loan bears interest at the rate of 4.50% per annum. In September 2021, the Company repaid the line of credit in full, Also in September 2021, the Company entered into a new line a credit in the amount of RMB 3,200,000 (approximately $0.8 million) on the same terms. The line of credit is due on September 2, 2022.
Bank of China [Member]
Lines of Credit (Details) [Line Items]
Line of credit description	On September 18, 2021 the Company obtained a line of credit for RMB 10,000,000 (approximately $1.54 million) with Bank of China. The loan bears interest at the rate of 3.85% per annum. The line of credit is due September 18, 2022. The loan is collateralized by the Company’s new production facility and the included production line equipment and machinery.
Interest amount				$ 15,157	$ 0

Lines of Credit (Details) - Sch

Lines of Credit (Details) - Schedule of principal payments - Lines of Credit [Member]	Mar. 31, 2022USD ($)
Debt Instrument [Line Items]
2022	$ 4,300,432
Total	$ 4,300,432

Convertible Note Payable (Detai

Convertible Note Payable (Details)	1 Months Ended				3 Months Ended		12 Months Ended
	Mar. 30, 2022USD ($)$ / shares	Mar. 21, 2022USD ($)$ / shares	Nov. 19, 2021$ / sharesshares	Nov. 17, 2021USD ($)	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)	Dec. 31, 2021$ / sharesshares	Apr. 19, 2022$ / sharesshares	Mar. 23, 2022shares
Convertible Note Payable (Details) [Line Items]
Notes matures				15 months
Original principal amount				$ 5,250,000
Investor consideration				5,000,000
Original issue discount				$ 250,000
Convertible balance					$ 4,950,000
Converted common stock price per share (in Dollars per share) | $ / shares					$ 3
Note converted into common stock					1,650,000
Interest accrues on note, description					Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default.
Redeem of outstanding note	$ 200,000	$ 100,000			$ 500,000
Percentage of common stock price on weighted average price					85.00%
Note redeemable into shares (in Shares) | shares			8,811,430		12,493,690		11,975,447
Weighted average price (in Dollars per share) | $ / shares	$ 0.3129	$ 0.3113	$ 0.595817
Total interest expense					$ 67,686	$ 0
Related payable interest	85.00%	85.00%
Common stock issued to investor (in Shares) | shares					639,181				321,233
Common Stock [Member]
Convertible Note Payable (Details) [Line Items]
Weighted average price (in Dollars per share) | $ / shares					$ 0.3962		$ 0.4384
Subsequent Event [Member]
Convertible Note Payable (Details) [Line Items]
Convertible shares (in Shares) | shares								3,300,000
Converted common stock price per share (in Dollars per share) | $ / shares								$ 1.5

Leases (Details)

Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Leases (Textual)
Operating lease cost	$ 21,419	$ 23,968
Cash flows from operating leases	22,495	$ 25,475
Operating lease right of use assets	107,094		$ 127,958
Operating leases liabilities	$ 108,990		$ 129,462
Weighted average remaining lease term	1 year 3 months
Weighted average discount rate	4.75%

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating lease liabilities	3 Months Ended
	Mar. 31, 2022USD ($)
Schedule of operating lease liabilities [Abstract]
2023	$ 89,978
2024	22,494
Total undiscounted cash flows	112,472
Less: Imputed interest	(3,482)
Total	108,990
Less: Operating lease liabilities, current portion	(86,672)
Operating lease liabilities, net of current portion	$ 22,318

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Enterprise income tax rate	25.00%
Net operating loss carryforwards for PRC tax	$ 23,800,000
Net operating loss expiration, description	Approximately $4.4 million of these carryforwards will expire in December 2022. The Company also has net operating losses for United States federal income tax purposes of approximately $8.0 million of which $5.1 million is available to offset future taxable income, if any, through 2039, and $2.9 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year.
Description of federal corporate income tax rate	The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.
Valuation allowance for deferred tax assets	$ 24,318,296	$ 23,982,509

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]
Banker’s acceptance notes	$ 14,146	$ 91,362
Total	14,146	91,362
Level 1 [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]
Banker’s acceptance notes
Total
Level 2 [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]
Banker’s acceptance notes	14,146	91,362
Total	14,146	91,362
Level 3 [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]
Banker’s acceptance notes
Total

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	1 Months Ended			3 Months Ended	12 Months Ended
	Mar. 30, 2022	Mar. 21, 2022	Nov. 19, 2021	Mar. 31, 2022	Dec. 31, 2021	Mar. 23, 2022	Dec. 27, 2021
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized				95,000,000	95,000,000
Common stock, par value (in Dollars per share)				$ 0.001	$ 0.001
Preferred stock, shares authorized				5,000,000	5,000,000
Preferred stock, par value (in Dollars per share)				$ 0.001	$ 0.001
After tax income, percentage				10.00%
Reserve account balances, percentage				50.00%
General and statutory capital reserves amount (in Dollars)				$ 8,145,000	$ 8,145,000
Redemption amount (in Dollars)	$ 200,000	$ 100,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)	$ 0.3129	$ 0.3113	$ 0.595817
Issuance of common stock				639,181		321,233
Common stock reserved shares							5,000,000
Total option outstanding				65,000
Additional shares available for issuance				5,000,000
2010 Incentive Plan [Member]
Stockholders' Equity (Details) [Line Items]
Common stock issued				9,000,000
Stock and stock option granted and outstanding				3,935,000
Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Common stock reserved shares							4,000,000
Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Common stock reserved shares							9,000,000

Risks & Uncertainties (Details)

Risks & Uncertainties (Details)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Risks & Uncertainties (Details) [Line Items]
Number of customers	3	3
Sales Revenue, Net [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	10.00%	10.00%
Accounts Receivable [Member] | Customer One [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	53.00%	51.90%
Accounts Receivable [Member] | Customer Two [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	11.40%	11.20%
Accounts Receivable [Member] | Customer Three [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	10.40%	10.20%
Raw Material Purchases [Member]
Risks & Uncertainties (Details) [Line Items]
Number of suppliers	2	2
Revenue One [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	32.50%	32.00%
Revenue Two [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	29.40%	27.00%
Revenue Three [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage		11.70%
Suppliers One [Member] | Raw Material Purchases [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	29.20%	45.10%
Suppliers Two [Member] | Raw Material Purchases [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	28.40%	20.10%
Revenue Two [Member] | Raw Material Purchases [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	12.70%